Patrick SoonShiong - NantHealth Insider

NantHealth Inc -- USA Stock  

USD 3.12  0.02  0.65%


Dr. Patrick SoonShiong, M.D. is Chairman of the Board, Chief Executive Officer, Founder of the Company. In 2011, he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network for the secure sharing of genetic and medical information, where he currently serves as Chief Executive Officer and Chairman of the board of directors. NantWorks is an affiliate and significant stockholder of NantHealth and Dr. Patrick SoonShiong indirectly controls all of the equity interests of NantWorks. Dr. Patrick SoonShiong, a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 95 issued patents on groundbreaking advancements spanning myriad fields. Dr. Patrick SoonShiong performed the worlds first encapsulated human islet transplant, the first engineered islet cell transplant and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nations first FDAapproved protein nanoparticle albuminbound delivery technology for the treatment of cancer. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. Dr. Patrick SoonShiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia. Dr. Patrick SoonShiong is a board certified surgeon and a fellow of the American College of Surgeons and of the Royal College of Physicians and Surgeons of Canada.
Age: 63  Founder Since 2016  Ph.D    
SoonShiong serves as Chairman of the Chan SoonShiong Family Foundation and Chairman and CEO of the Chan SoonShiong Institute of Molecular Medicine, a nonprofit medical research organization. He currently cochairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America.

Patrick SoonShiong Latest Insider Activity

Patrick SoonShiong over three months ago via Macroaxis 
NantKwest exotic insider transaction detected
Patrick SoonShiong over six months ago via Macroaxis 
tronc exotic insider transaction detected

Management Efficiency

The company has Return on Asset (ROA) of (12.75) % which means that for every 100 dollars spent on asset it generated loss of $12.75. This is way below average. Likewise, it shows return on total equity (ROE) of (60.87) % which implies that it produced no returns to current stockholders.
The company reports 194.3 M of total liabilities with total debt to equity ratio (D/E) of 93.0 which implies that the company may not be able to produce enough cash to satisfy its debt commitments. NantHealth Inc has Current Ratio of 2.33 indicating that it is in good position to pay out its debt commitments in time.

Entity Summary

NantHealth, Inc. operates as an evidence-based personalized healthcare company. The company was founded in 2010 and is headquartered in Culver City, California. NantHealth is traded on NASDAQ in USA.NantHealth Inc (NH) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 922 people. NantHealth is listed under Business Services category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add NantHealth Inc to your portfolio

Top Management

NantHealth Inc Leadership Team
Michael Blaszyk, Director
Kirk Calhoun, Director
Mark Burnett, Director
Patrick SoonShiong, Founder, Ph.D
Paul Holt, CFO, MBA
Michael Sitrick, Director

Stock Performance

NantHealth Performance Indicators